Cargando…

Early identification of atopic dermatitis patients in need of systemic immunosuppressive treatment

Detalles Bibliográficos
Autores principales:	Bakker, Daphne S., Drylewicz, Julia, Nierkens, Stefan, Knol, Edward F., Giovannone, Barbara, Delemarre, Eveline M., van der Schaft, Jorien, Balak, Deepak M. W., de Bruin‐Weller, Marjolein S., Thijs, Judith L.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2019
Materias:	Research Letters
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6973172/ https://www.ncbi.nlm.nih.gov/pubmed/31520450 http://dx.doi.org/10.1111/cea.13495

Ejemplares similares

EASI p‐EASI: Predicting disease severity in atopic dermatitis patients treated with dupilumab using a combination of serum biomarkers
por: Bakker, Daphne S., et al.
Publicado: (2020)

Rapid and Sustained Effect of Dupilumab on Work Productivity in Patients with Difficult-to-treat Atopic Dermatitis: Results from the Dutch BioDay Registry
por: ARIËNS, Lieneke F. M., et al.
Publicado: (2021)

High dupilumab levels in tear fluid of atopic dermatitis patients with moderate‐to‐severe ocular surface disease
por: Achten, Roselie, et al.
Publicado: (2023)

Goblet cell scarcity and conjunctival inflammation during treatment with dupilumab in patients with atopic dermatitis
por: Bakker, D.S., et al.
Publicado: (2019)

New Developments in Biomarkers for Atopic Dermatitis
por: Thijs, Judith L., et al.
Publicado: (2015)

Two‐year drug survival of dupilumab in a large cohort of difficult‐to‐treat adult atopic dermatitis patients compared to cyclosporine A and methotrexate: Results from the BioDay registry
por: Spekhorst, Lotte S., et al.
Publicado: (2020)

Ocular surface disease is common in moderate‐to‐severe atopic dermatitis patients
por: Achten, Roselie E., et al.
Publicado: (2022)

Conjunctival inflammation in dupilumab‐treated atopic dermatitis comprises a multicellular infiltrate with elevated T1/T17 cytokines: A case series study
por: Bakker, Daphne S., et al.
Publicado: (2021)

Real-World Treatment Patterns and Treatment Benefits among Adult Patients with Atopic Dermatitis: Results from the Atopic Dermatitis Patient Satisfaction and Unmet Need Survey
por: AUGUSTIN, Matthias, et al.
Publicado: (2022)

Nomenclature and clinical phenotypes of atopic dermatitis
por: Girolomoni, Giampiero, et al.
Publicado: (2021)

Developing integrated care pathways for atopic dermatitis—Challenges and unmet needs
por: Zuberbier, Torsten, et al.
Publicado: (2023)

Identification of Risk Factors for Dupilumab-associated Ocular Surface Disease in Patients with Atopic Dermatitis
por: ACHTEN, Roselie E., et al.
Publicado: (2022)

Dupilumab facial redness: Positive effect of itraconazole
por: de Beer, Fleur S.A., et al.
Publicado: (2019)

Economic and Humanistic Burden in Paediatric Patients with Atopic Dermatitis
por: ACHTEN, Roselie, et al.
Publicado: (2023)

Efficacy of Dupilumab in Atopic Dermatitis: The Patient’s Perspective
por: de Bruin-Weller, Marjolein, et al.
Publicado: (2021)

Effectiveness of Upadacitinib in Patients with Atopic Dermatitis including those with Inadequate Response to Dupilumab and/or Baricitinib: Results from the BioDay Registry
por: BOESJES, Celeste M., et al.
Publicado: (2023)

Food allergen sensitization pattern in adults in relation to severity of atopic dermatitis
por: Röckmann, Heike, et al.
Publicado: (2014)

Effect of dupilumab on hand eczema in patients with atopic dermatitis: An observational study
por: Oosterhaven, Jart A.F., et al.
Publicado: (2019)

Consistency of Response to Dupilumab in Adults with Moderate-to-Severe Atopic Dermatitis Over 1 Year
por: Blauvelt, Andrew, et al.
Publicado: (2022)

Dupilumab Provides Significant Clinical Benefit in a Phase 3 Trial in Adolescents with Uncontrolled Atopic Dermatitis Irrespective of Prior Systemic Immunosuppressant Use
por: DELEURAN, Mette, et al.
Publicado: (2021)

Dupilumab in Adults with Moderate-to-Severe Atopic Dermatitis and Prior Use of Systemic Non-Steroidal Immunosuppressants: Analysis of Four Phase 3 Trials
por: Griffiths, Christopher, et al.
Publicado: (2021)

Sick Leave and Factors Influencing Sick Leave in Adult Patients with Atopic Dermatitis: A Cross-Sectional Study
por: van Os-Medendorp, Harmieke, et al.
Publicado: (2015)

Dupilumab in daily practice for the treatment of pediatric atopic dermatitis: 28‐week clinical and biomarker results from the BioDay registry
por: Kamphuis, Esmé, et al.
Publicado: (2022)

Usage and Users of Online Self-Management Programs for Adult Patients With Atopic Dermatitis and Food Allergy: An Explorative Study
por: van Os-Medendorp, Harmieke, et al.
Publicado: (2015)

Immunoglobulin free light chains in adult atopic dermatitis patients do not correlate with disease severity
por: Thijs, J. L., et al.
Publicado: (2016)

The Treat-to-Target Project in Atopic Dermatitis: One Year On
por: DE BRUIN-WELLER, Marjolein, et al.
Publicado: (2023)

Indirect Treatment Comparison of Baricitinib versus Dupilumab in Adults with Moderate-to-Severe Atopic Dermatitis
por: de Bruin-Weller, Marjolein S., et al.
Publicado: (2022)

Expert Perspectives on Key Parameters that Impact Interpretation of Randomized Clinical Trials in Moderate-to-Severe Atopic Dermatitis
por: Silverberg, Jonathan I., et al.
Publicado: (2021)

Immunosuppressive and Immunomodulating Therapy for Atopic Dermatitis in Pregnancy: An Appraisal of the Literature
por: Heilskov, Sofine, et al.
Publicado: (2020)

Effect of immunosuppressive treatment on biomarkers in adult atopic dermatitis patients
por: Roekevisch, E., et al.
Publicado: (2020)

Daily Practice Experience of Baricitinib Treatment for Patients with Difficult-to-Treat Atopic Dermatitis: Results from the BioDay Registry
por: BOESJES, Celeste M., et al.
Publicado: (2022)

The positive effect of dupilumab on comorbid asthma in patients with atopic dermatitis
por: Spekhorst, Lotte S., et al.
Publicado: (2023)

Dupilumab with Topical Corticosteroids Provides Rapid and Sustained Improvement in Adults with Moderate-to-Severe Atopic Dermatitis Across Anatomic Regions Over 52 Weeks
por: Blauvelt, Andrew, et al.
Publicado: (2021)

Atopic dermatitis phenotypes and the need for personalized medicine
por: Cabanillas, Beatriz, et al.
Publicado: (2017)

Atopic Dermatitis: Clinical Aspects and Unmet Needs
por: Lobefaro, Fabio, et al.
Publicado: (2022)

The long‐term effect of dupilumab on chronic hand eczema in patients with moderate to severe atopic dermatitis—52 week results from the Dutch BioDay Registry
por: Voorberg, Angelique N., et al.
Publicado: (2022)

Dupilumab Provides Rapid and Sustained Clinically Meaningful Responses in Adults with Moderate-to-severe Atopic Dermatitis
por: SILVERBERG, Jonathan I., et al.
Publicado: (2021)

Conjunctivitis in Dupilumab Clinical Trials for Adolescents with Atopic Dermatitis or Asthma
por: Bansal, Ashish, et al.
Publicado: (2021)

Patient-Reported Ocular Disorders and Symptoms in Adults with Moderate-to-Severe Atopic Dermatitis: Screening and Baseline Survey Data from a Clinical Trial
por: Weyne, Jonathan, et al.
Publicado: (2020)

Definition of Clinically Meaningful Within-Patient Changes in POEM and CDLQI in Children 6 to 11 Years of Age with Severe Atopic Dermatitis
por: Simpson, Eric L., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_c278seanvsd8icjfjeotk0j6fb